Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects

To address the limited bioavailability and intolerance of the conventional itraconazole (ITZ) formulations, a new formulation labeled super bioavailability (SUBA) itraconazole has been developed; however, the specific effects of food and gastric pH are unknown. This study evaluated the pharmacokinetic profile of SUBA itraconazole under fasting and fed conditions, as well as with the concomitant administration of a proton pump inhibitor. ABSTRACT To address the limited bioavailability and intolerance of the conventional itraconazole (ITZ) formulations, a new formulation labeled super bioavailability (SUBA) itraconazole has been developed; however, the specific effects of food and gastric pH are unknown. This study evaluated the pharmacokinetic profile of SUBA itraconazole under fasting and fed conditions, as well as with the concomitant administration of a proton pump inhibitor. First, the effect of food was assessed in an open-label, randomized, crossover bioavailability study of 65-mg SUBA itraconazole capsules (2 65-mg capsules twice a day) in healthy adults (n = 20) under fasting and fed conditions to steady-state levels. Second, an open-label, two-treatment, fixed-sequence comparative bioavailability study in healthy adults (n = 28) under fasted conditions compared the pharmacokinetics of a single oral dose of SUBA itraconazole capsules (2 65-mg capsules/day) with and without coadministration of daily omeprazole delayed-release capsules (1 40-mg capsule/day) under steady-state conditions. In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found. When dosed concomitantly with omeprazole, there was a 22% increase in the total plasma exposure of ITZ, as measured by the area under the concentration-time curve from time zero to infinity (P = 0.0069), and a 31% increase in the peak plasma exposure of ITZ, as measured by the maximum concentration (P = 0.0083).

[1]  Itraconazole , 2020, Reactions Weekly.

[2]  G. Thompson,et al.  Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation , 2018, Mycoses.

[3]  I. Kerridge,et al.  Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation , 2017, The Journal of antimicrobial chemotherapy.

[4]  Alison M Semrad,et al.  In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia , 2017, Antimicrobial Agents and Chemotherapy.

[5]  A. Odermatt,et al.  Inhibition of 11[beta]-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole , 2017 .

[6]  A. Odermatt,et al.  Inhibition of 11 b-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole , 2017 .

[7]  R. Upton,et al.  Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States , 2015, Antimicrobial Agents and Chemotherapy.

[8]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[9]  P. Pappas,et al.  Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  MANUPAT LOHITNAVY,et al.  Reduced oral itraconazole bioavailability by antacid suspension , 2005, Journal of clinical pharmacy and therapeutics.

[11]  G. Drusano How does a patient maximally benefit from anti-infective chemotherapy? , 2004, Clinical Infectious Diseases.

[12]  M. Potter,et al.  The Role of Itraconazole in Preventing and Treating Systemic Fungal Infections in Immunocompromised Patients , 2004, Acta Haematologica.

[13]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[14]  A. Peer,et al.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[15]  C. Hamilton,et al.  A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. , 2003, The Journal of antimicrobial chemotherapy.

[16]  H. Prentice,et al.  Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Leutner,et al.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.

[18]  S. Sriwiriyajan,et al.  Effect of omeprazole on the pharmacokinetics of itraconazole , 1998, European Journal of Clinical Pharmacology.

[19]  J. Barone,et al.  Food Interaction and Steady‐State Pharmacokinetics of Itraconazole Oral Solution in Healthy Volunteers , 1998, Pharmacotherapy.

[20]  Y. Yazaki,et al.  Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole , 1998, Hematological oncology.

[21]  M. Klausner,et al.  Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers , 1997, Journal of clinical pharmacology.

[22]  B. Gazzard,et al.  Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. , 1997, Journal of clinical pathology.

[23]  S. Jaruratanasirikul,et al.  Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole , 1997, European Journal of Clinical Pharmacology.

[24]  J. Perfect,et al.  NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. , 1994, The American journal of medicine.

[25]  R. Yeates,et al.  Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. , 1994, Drugs under experimental and clinical research.

[26]  Anosh Joseph,et al.  Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers , 1993, Antimicrobial Agents and Chemotherapy.

[27]  J. Dunn,et al.  High-dose itraconazole in the treatment of severe mycoses , 1991, Antimicrobial Agents and Chemotherapy.

[28]  R. M. Tucker,et al.  Adverse events associated with itraconazole in 189 patients on chronic therapy. , 1990, The Journal of antimicrobial chemotherapy.

[29]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.

[30]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[31]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.